kpc cells Search Results


99
CancerTools Org cancer research uk glasgow
Cancer Research Uk Glasgow, supplied by CancerTools Org, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/kpc+cells/KPC+-+C57%2FBL6+background/bio_rxiv__64898__2026__01__07__698161-28-15-22
Average 99 stars, based on 1 article reviews
cancer research uk glasgow - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

99
CancerTools Org kpc
(A) Immunofluorescence imaging of Tie2Hi/VEGFAHi macrophages in TMEM doorways in sequential sections. Endothelial cells (EC), macrophage (M) and tumor tissue (TC). In the merge panel, a mask for IBA1 macrophage was created in ImageJ ® for a better visualization of Tie2. Scale bar,10μm. (B and C) Quantification of Tie2+ macrophages in tumor area and withim TMEM doorway area <t>of</t> <t>KPCY</t> T-low (B) and <t>KPC</t> (C) tumors. -total macrophages. -Tie2 positive macrophages. (D) Western blot analysis of phospho-Tie2 immunoprecipitated from extracts of KPC, KPCY T-low, RAW 264.7 or 3B-11 cells treated with Rebastinib +/- Angiopoietin 2. (E) Experimental design of the subluminal to luminal trans-endothelial migration (iTEM) assay. Macrophages = red. Tumor cells = green. The tumor cells (green) are considered transendothelial migrating cells when they are crossing the endothelial layer (pink). (F) Representative image of iTEM assay from confocal microscope. Macrophages = red. Tumor cells = green. Endothelial layer = pink. Quantitation of trans-endothelial migration of KPCY T-low (G) and KPC (H). In KPCY T-low and KPC, we observed an increase of transendothelial migration from 3 cells/field to 12.65 cells/field and 6 cells/field to 16.65 cells/field respectively, in the presence of macrophages (p<0.05), following by a decrease to 8.46 cells/field and 8.46 cells/field after rebastinib treatment (p<0.05). Co-culture with macrophages significantly increased migration, which was inhibited by the Tie2 inhibitor rebastinib. Data are presented as mean ± SEM; (n ≥ 10 per group). *P < 0.05, by one-way ANOVA with Tukey’s post hoc test.
Kpc, supplied by CancerTools Org, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/kpc+cells/KPC+-+Mixed+Background/bio_rxiv__64898__2025__12__05__692608-173-0-4
Average 99 stars, based on 1 article reviews
kpc - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

90
Cancer Research Technology Limited pancreatic cancer cell line kpc
(A) Immunofluorescence imaging of Tie2Hi/VEGFAHi macrophages in TMEM doorways in sequential sections. Endothelial cells (EC), macrophage (M) and tumor tissue (TC). In the merge panel, a mask for IBA1 macrophage was created in ImageJ ® for a better visualization of Tie2. Scale bar,10μm. (B and C) Quantification of Tie2+ macrophages in tumor area and withim TMEM doorway area <t>of</t> <t>KPCY</t> T-low (B) and <t>KPC</t> (C) tumors. -total macrophages. -Tie2 positive macrophages. (D) Western blot analysis of phospho-Tie2 immunoprecipitated from extracts of KPC, KPCY T-low, RAW 264.7 or 3B-11 cells treated with Rebastinib +/- Angiopoietin 2. (E) Experimental design of the subluminal to luminal trans-endothelial migration (iTEM) assay. Macrophages = red. Tumor cells = green. The tumor cells (green) are considered transendothelial migrating cells when they are crossing the endothelial layer (pink). (F) Representative image of iTEM assay from confocal microscope. Macrophages = red. Tumor cells = green. Endothelial layer = pink. Quantitation of trans-endothelial migration of KPCY T-low (G) and KPC (H). In KPCY T-low and KPC, we observed an increase of transendothelial migration from 3 cells/field to 12.65 cells/field and 6 cells/field to 16.65 cells/field respectively, in the presence of macrophages (p<0.05), following by a decrease to 8.46 cells/field and 8.46 cells/field after rebastinib treatment (p<0.05). Co-culture with macrophages significantly increased migration, which was inhibited by the Tie2 inhibitor rebastinib. Data are presented as mean ± SEM; (n ≥ 10 per group). *P < 0.05, by one-way ANOVA with Tukey’s post hoc test.
Pancreatic Cancer Cell Line Kpc, supplied by Cancer Research Technology Limited, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/kpc+cells/pancreatic+cancer+cell+line+kpc/pm40050802-144-1-9
Average 90 stars, based on 1 article reviews
pancreatic cancer cell line kpc - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Cold Spring Harbor Laboratory Meetings kpc mice
TERT expression in human and mouse PDAC tissues. (A) Representative H&E staining and TERT IHC analysis in human normal pancreas and PDAC tissues (G2/G3 tumor grade). PDAC tissues were scored as negative (-), positive (+), highly positive (++) according to hTERT antigen. (B) Patients with pancreatic cancer were stratified according to TERT expression. (C) Representative TERT IHC analysis (top panel) and H&E staining (bottom panel) in pancreas specimens isolated from <t>KPC</t> <t>mice</t> at different stages of neoplastic evolution, or in tumors isolated from C57BL/6 mice orthotopically injected with FC1242 cells (D) and sacrificed at different time points (10–30 days) from tumor challenge. Scale bar (A, C, D), 100 µm. (E) TERT activity and expression in normal pancreatic cells and KPC-derived cell lines by TRAP assay (top panel; untreated samples, black; heat-inactivated-negative control samples, white; TPG) and Western blot (bottom panel), respectively. Representative samples are shown. IHC, immunohistochemistry; PDAC, pancreatic ductal adenocarcinoma; TERT, telomerase; TPG, total product generated.
Kpc Mice, supplied by Cold Spring Harbor Laboratory Meetings, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/kpc+cells/kpc+cell+line/pmc08756272-48-0-9
Average 90 stars, based on 1 article reviews
kpc mice - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Mediatech kpc cell line
TERT expression in human and mouse PDAC tissues. (A) Representative H&E staining and TERT IHC analysis in human normal pancreas and PDAC tissues (G2/G3 tumor grade). PDAC tissues were scored as negative (-), positive (+), highly positive (++) according to hTERT antigen. (B) Patients with pancreatic cancer were stratified according to TERT expression. (C) Representative TERT IHC analysis (top panel) and H&E staining (bottom panel) in pancreas specimens isolated from <t>KPC</t> <t>mice</t> at different stages of neoplastic evolution, or in tumors isolated from C57BL/6 mice orthotopically injected with FC1242 cells (D) and sacrificed at different time points (10–30 days) from tumor challenge. Scale bar (A, C, D), 100 µm. (E) TERT activity and expression in normal pancreatic cells and KPC-derived cell lines by TRAP assay (top panel; untreated samples, black; heat-inactivated-negative control samples, white; TPG) and Western blot (bottom panel), respectively. Representative samples are shown. IHC, immunohistochemistry; PDAC, pancreatic ductal adenocarcinoma; TERT, telomerase; TPG, total product generated.
Kpc Cell Line, supplied by Mediatech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/kpc+cells/kpc+cell+line/pm40209809-434-5-16
Average 90 stars, based on 1 article reviews
kpc cell line - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Jackson Laboratory kpc fc1242 pdac cells
TERT expression in human and mouse PDAC tissues. (A) Representative H&E staining and TERT IHC analysis in human normal pancreas and PDAC tissues (G2/G3 tumor grade). PDAC tissues were scored as negative (-), positive (+), highly positive (++) according to hTERT antigen. (B) Patients with pancreatic cancer were stratified according to TERT expression. (C) Representative TERT IHC analysis (top panel) and H&E staining (bottom panel) in pancreas specimens isolated from <t>KPC</t> <t>mice</t> at different stages of neoplastic evolution, or in tumors isolated from C57BL/6 mice orthotopically injected with FC1242 cells (D) and sacrificed at different time points (10–30 days) from tumor challenge. Scale bar (A, C, D), 100 µm. (E) TERT activity and expression in normal pancreatic cells and KPC-derived cell lines by TRAP assay (top panel; untreated samples, black; heat-inactivated-negative control samples, white; TPG) and Western blot (bottom panel), respectively. Representative samples are shown. IHC, immunohistochemistry; PDAC, pancreatic ductal adenocarcinoma; TERT, telomerase; TPG, total product generated.
Kpc Fc1242 Pdac Cells, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/kpc+cells/kpc+fc1242+pdac+cells/pmc06863392__mmc2-325-9-32
Average 90 stars, based on 1 article reviews
kpc fc1242 pdac cells - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
BioMimetic Therapeutics m2-like macrophages peptides (m2pep)
Nanoparticle-based therapeutic strategies for enhanced PDAC immunotherapy.
M2 Like Macrophages Peptides (M2pep), supplied by BioMimetic Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/kpc+cells/m2pep+++kpc+cell+membrane/pmc09607590-37-8-14
Average 90 stars, based on 1 article reviews
m2-like macrophages peptides (m2pep) - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Johns Hopkins HealthCare kpc cells
Nanoparticle-based therapeutic strategies for enhanced PDAC immunotherapy.
Kpc Cells, supplied by Johns Hopkins HealthCare, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/kpc+cells/kpc+cells/pm37867243-279-9-16
Average 90 stars, based on 1 article reviews
kpc cells - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Shanghai Model Organisms Center kpc-cldn18.2 cells
Nanoparticle-based therapeutic strategies for enhanced PDAC immunotherapy.
Kpc Cldn18.2 Cells, supplied by Shanghai Model Organisms Center, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/kpc+cells/kpc+cldn18+2+cells/pmc10926568-21-0-22
Average 90 stars, based on 1 article reviews
kpc-cldn18.2 cells - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Charles River Laboratories kpc cells
Nanoparticle-based therapeutic strategies for enhanced PDAC immunotherapy.
Kpc Cells, supplied by Charles River Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/kpc+cells/kpc+cells/pmc09643498-213-7-26
Average 90 stars, based on 1 article reviews
kpc cells - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Jackson Laboratory kpc-mt3 cells
Nanoparticle-based therapeutic strategies for enhanced PDAC immunotherapy.
Kpc Mt3 Cells, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/kpc+cells/kpc+mt3+cells/pmc09701142-325-30-45
Average 90 stars, based on 1 article reviews
kpc-mt3 cells - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Absolute Biotech Inc kpc cell line
Nanoparticle-based therapeutic strategies for enhanced PDAC immunotherapy.
Kpc Cell Line, supplied by Absolute Biotech Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/kpc+cells/kpc+cell+line/pmc11685413-232-1-16
Average 90 stars, based on 1 article reviews
kpc cell line - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

Image Search Results


(A) Immunofluorescence imaging of Tie2Hi/VEGFAHi macrophages in TMEM doorways in sequential sections. Endothelial cells (EC), macrophage (M) and tumor tissue (TC). In the merge panel, a mask for IBA1 macrophage was created in ImageJ ® for a better visualization of Tie2. Scale bar,10μm. (B and C) Quantification of Tie2+ macrophages in tumor area and withim TMEM doorway area of KPCY T-low (B) and KPC (C) tumors. -total macrophages. -Tie2 positive macrophages. (D) Western blot analysis of phospho-Tie2 immunoprecipitated from extracts of KPC, KPCY T-low, RAW 264.7 or 3B-11 cells treated with Rebastinib +/- Angiopoietin 2. (E) Experimental design of the subluminal to luminal trans-endothelial migration (iTEM) assay. Macrophages = red. Tumor cells = green. The tumor cells (green) are considered transendothelial migrating cells when they are crossing the endothelial layer (pink). (F) Representative image of iTEM assay from confocal microscope. Macrophages = red. Tumor cells = green. Endothelial layer = pink. Quantitation of trans-endothelial migration of KPCY T-low (G) and KPC (H). In KPCY T-low and KPC, we observed an increase of transendothelial migration from 3 cells/field to 12.65 cells/field and 6 cells/field to 16.65 cells/field respectively, in the presence of macrophages (p<0.05), following by a decrease to 8.46 cells/field and 8.46 cells/field after rebastinib treatment (p<0.05). Co-culture with macrophages significantly increased migration, which was inhibited by the Tie2 inhibitor rebastinib. Data are presented as mean ± SEM; (n ≥ 10 per group). *P < 0.05, by one-way ANOVA with Tukey’s post hoc test.

Journal: bioRxiv

Article Title: TMEM Doorway Mediated Metastasis in Pancreatic Ductal Adenocarcinoma by Tie2 Signaling

doi: 10.64898/2025.12.05.692608

Figure Lengend Snippet: (A) Immunofluorescence imaging of Tie2Hi/VEGFAHi macrophages in TMEM doorways in sequential sections. Endothelial cells (EC), macrophage (M) and tumor tissue (TC). In the merge panel, a mask for IBA1 macrophage was created in ImageJ ® for a better visualization of Tie2. Scale bar,10μm. (B and C) Quantification of Tie2+ macrophages in tumor area and withim TMEM doorway area of KPCY T-low (B) and KPC (C) tumors. -total macrophages. -Tie2 positive macrophages. (D) Western blot analysis of phospho-Tie2 immunoprecipitated from extracts of KPC, KPCY T-low, RAW 264.7 or 3B-11 cells treated with Rebastinib +/- Angiopoietin 2. (E) Experimental design of the subluminal to luminal trans-endothelial migration (iTEM) assay. Macrophages = red. Tumor cells = green. The tumor cells (green) are considered transendothelial migrating cells when they are crossing the endothelial layer (pink). (F) Representative image of iTEM assay from confocal microscope. Macrophages = red. Tumor cells = green. Endothelial layer = pink. Quantitation of trans-endothelial migration of KPCY T-low (G) and KPC (H). In KPCY T-low and KPC, we observed an increase of transendothelial migration from 3 cells/field to 12.65 cells/field and 6 cells/field to 16.65 cells/field respectively, in the presence of macrophages (p<0.05), following by a decrease to 8.46 cells/field and 8.46 cells/field after rebastinib treatment (p<0.05). Co-culture with macrophages significantly increased migration, which was inhibited by the Tie2 inhibitor rebastinib. Data are presented as mean ± SEM; (n ≥ 10 per group). *P < 0.05, by one-way ANOVA with Tukey’s post hoc test.

Article Snippet: KPC ( Cat.#: 153600: Cancer tools.org ) , KPCY T-low (6419c5) , or KPCY C-EMT 3077 (provided by Ben Z. Stanger) , murine macrophage cell line RAW264.7 (ATCC-provided by Dianne Cox), and murine endothelial cells 3B11 (ATCC - provided by Camille Duran) were cultured in Dulbecco’s Modified Eagle Medium (DMEM) (cat# SH30243, Hyclone, GE Healthcare Life Sciences, Logan, UT, USA) supplemented with 10% fetal bovine serum (FBS) (cat# S11550, Atlanta Biologicals, Flowery Branch, GA, USA).

Techniques: Immunofluorescence, Imaging, Western Blot, Immunoprecipitation, Migration, Microscopy, Quantitation Assay, Co-Culture Assay

(A) panel 1 shows TMEM doorways, visualized by immunohistochemistry (IHC) staining for Mena, Iba-1, and endomucin. The three cells of the TMEM doorway (contained in black circle, with the three cells forming the TMEM doorway indicated with the yellow triangle) are the TMEM doorway endothelial cell (TEC, endomucin stained in blue), TMEM doorway macrophage (TM, Iba1 stained in brown), and TMEM doorway tumor cell (TTC, Mena stained in pink). Panels 2-4 show different staining channels of the sequential tissue section 2 aligned with the IHC stained section (panel 1) with immunofluorescence (IF) with antibodies against endomucin (panel 3 yellow), dextran (panel 4 pink) and nuclear stain DAPI (blue). Active versus inactive TMEM doorways were distinguished by the presence of extravascular dextran staining (panel), which indicates that the vessel had a TMEM doorway-associated vascular opening (TAVO). Scale bars=20μm. (B-H) Mice were treated with control chow or ∼0.44 mg/day of rebastinib for 3 weeks. (B and D) Quantification of TMEM doorway density in 10 high-power fields (HPFs; no significant difference) in KPCY T-low (B) and KPC tumors (D). (C and E) Immunofluorescence measurement of extravascular dextran levels in Tie2 + TMEM doorways indicate significant inhibition of TMEM doorways by rebastinib inKPCY T – low tumors (C) and KPC tumors (E). TMEM doorways were identified in the IF-stained sections as described above. Active TMEM doorways were identified by the presence of extravascular dextran which is not present in inactive TMEM doorways. *p<0.05. (F) Disseminated tumor cells in the liver stained with p53 (red). Increased magnification of field of the p53 positive cells is shown in the yellow box. The left bottom is a representative image of control and right bottom of rebastinib treated group in magnified fields. (G-H) Quantification of DTCs in the liver of animals as compared to the control with rebastinib treated groups showing significant inhibition of DTC levels. (G) KPCY T-low (H) KPC where each dot is a separate mouse. *p<0.05, analyzed by Student’s t-test. N=8.

Journal: bioRxiv

Article Title: TMEM Doorway Mediated Metastasis in Pancreatic Ductal Adenocarcinoma by Tie2 Signaling

doi: 10.64898/2025.12.05.692608

Figure Lengend Snippet: (A) panel 1 shows TMEM doorways, visualized by immunohistochemistry (IHC) staining for Mena, Iba-1, and endomucin. The three cells of the TMEM doorway (contained in black circle, with the three cells forming the TMEM doorway indicated with the yellow triangle) are the TMEM doorway endothelial cell (TEC, endomucin stained in blue), TMEM doorway macrophage (TM, Iba1 stained in brown), and TMEM doorway tumor cell (TTC, Mena stained in pink). Panels 2-4 show different staining channels of the sequential tissue section 2 aligned with the IHC stained section (panel 1) with immunofluorescence (IF) with antibodies against endomucin (panel 3 yellow), dextran (panel 4 pink) and nuclear stain DAPI (blue). Active versus inactive TMEM doorways were distinguished by the presence of extravascular dextran staining (panel), which indicates that the vessel had a TMEM doorway-associated vascular opening (TAVO). Scale bars=20μm. (B-H) Mice were treated with control chow or ∼0.44 mg/day of rebastinib for 3 weeks. (B and D) Quantification of TMEM doorway density in 10 high-power fields (HPFs; no significant difference) in KPCY T-low (B) and KPC tumors (D). (C and E) Immunofluorescence measurement of extravascular dextran levels in Tie2 + TMEM doorways indicate significant inhibition of TMEM doorways by rebastinib inKPCY T – low tumors (C) and KPC tumors (E). TMEM doorways were identified in the IF-stained sections as described above. Active TMEM doorways were identified by the presence of extravascular dextran which is not present in inactive TMEM doorways. *p<0.05. (F) Disseminated tumor cells in the liver stained with p53 (red). Increased magnification of field of the p53 positive cells is shown in the yellow box. The left bottom is a representative image of control and right bottom of rebastinib treated group in magnified fields. (G-H) Quantification of DTCs in the liver of animals as compared to the control with rebastinib treated groups showing significant inhibition of DTC levels. (G) KPCY T-low (H) KPC where each dot is a separate mouse. *p<0.05, analyzed by Student’s t-test. N=8.

Article Snippet: KPC ( Cat.#: 153600: Cancer tools.org ) , KPCY T-low (6419c5) , or KPCY C-EMT 3077 (provided by Ben Z. Stanger) , murine macrophage cell line RAW264.7 (ATCC-provided by Dianne Cox), and murine endothelial cells 3B11 (ATCC - provided by Camille Duran) were cultured in Dulbecco’s Modified Eagle Medium (DMEM) (cat# SH30243, Hyclone, GE Healthcare Life Sciences, Logan, UT, USA) supplemented with 10% fetal bovine serum (FBS) (cat# S11550, Atlanta Biologicals, Flowery Branch, GA, USA).

Techniques: Immunohistochemistry, Staining, Immunofluorescence, Control, Inhibition

TERT expression in human and mouse PDAC tissues. (A) Representative H&E staining and TERT IHC analysis in human normal pancreas and PDAC tissues (G2/G3 tumor grade). PDAC tissues were scored as negative (-), positive (+), highly positive (++) according to hTERT antigen. (B) Patients with pancreatic cancer were stratified according to TERT expression. (C) Representative TERT IHC analysis (top panel) and H&E staining (bottom panel) in pancreas specimens isolated from KPC mice at different stages of neoplastic evolution, or in tumors isolated from C57BL/6 mice orthotopically injected with FC1242 cells (D) and sacrificed at different time points (10–30 days) from tumor challenge. Scale bar (A, C, D), 100 µm. (E) TERT activity and expression in normal pancreatic cells and KPC-derived cell lines by TRAP assay (top panel; untreated samples, black; heat-inactivated-negative control samples, white; TPG) and Western blot (bottom panel), respectively. Representative samples are shown. IHC, immunohistochemistry; PDAC, pancreatic ductal adenocarcinoma; TERT, telomerase; TPG, total product generated.

Journal: Journal for Immunotherapy of Cancer

Article Title: Interrupting the nitrosative stress fuels tumor-specific cytotoxic T lymphocytes in pancreatic cancer

doi: 10.1136/jitc-2021-003549

Figure Lengend Snippet: TERT expression in human and mouse PDAC tissues. (A) Representative H&E staining and TERT IHC analysis in human normal pancreas and PDAC tissues (G2/G3 tumor grade). PDAC tissues were scored as negative (-), positive (+), highly positive (++) according to hTERT antigen. (B) Patients with pancreatic cancer were stratified according to TERT expression. (C) Representative TERT IHC analysis (top panel) and H&E staining (bottom panel) in pancreas specimens isolated from KPC mice at different stages of neoplastic evolution, or in tumors isolated from C57BL/6 mice orthotopically injected with FC1242 cells (D) and sacrificed at different time points (10–30 days) from tumor challenge. Scale bar (A, C, D), 100 µm. (E) TERT activity and expression in normal pancreatic cells and KPC-derived cell lines by TRAP assay (top panel; untreated samples, black; heat-inactivated-negative control samples, white; TPG) and Western blot (bottom panel), respectively. Representative samples are shown. IHC, immunohistochemistry; PDAC, pancreatic ductal adenocarcinoma; TERT, telomerase; TPG, total product generated.

Article Snippet: KPC mice were kindly supplied by Dr D Tuveson (Cold Spring Harbor Laboratory, New York, USA).

Techniques: Expressing, Staining, Isolation, Injection, Activity Assay, Derivative Assay, TRAP Assay, Negative Control, Western Blot, Immunohistochemistry, Generated

TERT-based ACT restrains PDAC progression. (A, B) C57Bl/6 mice were orthotopically challenged with mouse KPC-derived FC1242-Luc (A) or FC1199-Luc (B) cells. Mice were randomized in two groups which received mTERT-specific (treatment group, n=10) or OVA-specific (control group n=10) mouse CTLs ACT. Therapeutic efficacy was evaluated over time in terms of tumor progression (top panel) and survival (bottom panel). (C) Tracking of adoptively transferred T lymphocytes in PDAC specimens. Congenic immunocompetent CD45.1 mice were orthotopically challenged with mouse KPC-derived FC1242 or FC1199 cells and subjected to CD45.2 + mTERT-specific mouse CTLs ACT or left untreated. Tumor-infiltrating T lymphocytes (CD3 + CD8 + cells) were stained with both CD45.1 (endogeneous lymphocytes) and CD45.2 (transferred lymphocytes) antibodies. (D) KPC mice were enrolled in two groups receiving mTERT-specific (treatment group, n=20) or OVA-specific (control group n=20) mouse CTLs ACT. Therapeutic efficacy was evaluated over time by Kaplan-Meier curves for OS. (E) Immunodeficient NOG mice were orthotopically challenged with human PDAC HLA-A2 + HF2_Luc cell line. Mice were randomized in two groups which received, respectively, hTERT-specific (treatment group) or HCV-specific (control group) engineered human T lymphocytes. Tumor growth was monitored by in vivo imaging (left panel). Therapeutic efficacy was evaluated over time in terms of tumor progression (middle panel) and survival (right panel). Tumor growth was evaluated by in vivo imaging (IVIS-Perkin Elmer: A, B, E; Vevo ultrasound imaging: D): a representative image for each analyzed time point was reported (A, B, E). Data are reported as mean±SE of a representative experiment of two (A, B, E) and three (C) independent replicates. Statistical analysis was performed using one-wayANOVA (A, B, E), Mantel-Haenszel (long-rank) test (A, B, D, E), two-tailed Student’s t -test (C). ACT, adoptive cell therapy; ANOVA, analysis of variance; CTL, cytotoxic T lymphocyte; OS, overall survival; PDAC, pancreatic ductal adenocarcinoma.

Journal: Journal for Immunotherapy of Cancer

Article Title: Interrupting the nitrosative stress fuels tumor-specific cytotoxic T lymphocytes in pancreatic cancer

doi: 10.1136/jitc-2021-003549

Figure Lengend Snippet: TERT-based ACT restrains PDAC progression. (A, B) C57Bl/6 mice were orthotopically challenged with mouse KPC-derived FC1242-Luc (A) or FC1199-Luc (B) cells. Mice were randomized in two groups which received mTERT-specific (treatment group, n=10) or OVA-specific (control group n=10) mouse CTLs ACT. Therapeutic efficacy was evaluated over time in terms of tumor progression (top panel) and survival (bottom panel). (C) Tracking of adoptively transferred T lymphocytes in PDAC specimens. Congenic immunocompetent CD45.1 mice were orthotopically challenged with mouse KPC-derived FC1242 or FC1199 cells and subjected to CD45.2 + mTERT-specific mouse CTLs ACT or left untreated. Tumor-infiltrating T lymphocytes (CD3 + CD8 + cells) were stained with both CD45.1 (endogeneous lymphocytes) and CD45.2 (transferred lymphocytes) antibodies. (D) KPC mice were enrolled in two groups receiving mTERT-specific (treatment group, n=20) or OVA-specific (control group n=20) mouse CTLs ACT. Therapeutic efficacy was evaluated over time by Kaplan-Meier curves for OS. (E) Immunodeficient NOG mice were orthotopically challenged with human PDAC HLA-A2 + HF2_Luc cell line. Mice were randomized in two groups which received, respectively, hTERT-specific (treatment group) or HCV-specific (control group) engineered human T lymphocytes. Tumor growth was monitored by in vivo imaging (left panel). Therapeutic efficacy was evaluated over time in terms of tumor progression (middle panel) and survival (right panel). Tumor growth was evaluated by in vivo imaging (IVIS-Perkin Elmer: A, B, E; Vevo ultrasound imaging: D): a representative image for each analyzed time point was reported (A, B, E). Data are reported as mean±SE of a representative experiment of two (A, B, E) and three (C) independent replicates. Statistical analysis was performed using one-wayANOVA (A, B, E), Mantel-Haenszel (long-rank) test (A, B, D, E), two-tailed Student’s t -test (C). ACT, adoptive cell therapy; ANOVA, analysis of variance; CTL, cytotoxic T lymphocyte; OS, overall survival; PDAC, pancreatic ductal adenocarcinoma.

Article Snippet: KPC mice were kindly supplied by Dr D Tuveson (Cold Spring Harbor Laboratory, New York, USA).

Techniques: Derivative Assay, Control, Drug discovery, Staining, In Vivo Imaging, Imaging, Two Tailed Test

AT38 renders PDAC responsive to immunotherapy. (A) C57BL/6 mice were orthotopically challenged with FC1242 cells, randomized in four groups receiving, respectively, vehicle (CTRL, n=10), AT38 only (AT38, n=10), mTERT-specific mouse CTLs only (TERT-ACT, n=10), AT38+mTERT-specific mouse CTLs (n=10). Tumor growth was evaluated by in vivo imaging: a representative image for each analyzed time point was reported (left panel). Therapeutic efficacy was evaluated over time in terms of tumor progression (middle panels) and survival (right panel). Data are reported as mean±SD of a representative experiment of two independent replicates. Statistical analysis was performed using one-way ANOVA followed by Tukey’s test for tumor growth and Mantel-Haenszel (long-rank) test for survival. (B) KPC mice were enrolled in four groups receiving, respectively, vehicle (CTRL), AT38 only (AT38), mTERT-specific mouse CTLs only (TERT-ACT), AT38+mTERT-specific mouse CTLs (AT38+TERT ACT). Tumor growth was evaluated by high-resolution ultrasound images of pancreatic tumor in KPC mice before (-, left panel) and 10 days after treatment (+, left panel) and shown as waterfall plots (right panel) of therapeutic response. (C) Kaplan-Meier curves for overall survival of KPC mice with invasive disease untreated (n=25) or treated with AT38 (n=20), TERT-ACT (n=15) or combined approach (n=20). Statistical analysis was performed using Mantel-Haenszel (long-rank) test. ACT, adoptive cell therapy; ANOVA, analysis of variance; CTL, cytotoxic T lymphocyte; PDAC, pancreatic ductal adenocarcinoma; TERT, telomerase.

Journal: Journal for Immunotherapy of Cancer

Article Title: Interrupting the nitrosative stress fuels tumor-specific cytotoxic T lymphocytes in pancreatic cancer

doi: 10.1136/jitc-2021-003549

Figure Lengend Snippet: AT38 renders PDAC responsive to immunotherapy. (A) C57BL/6 mice were orthotopically challenged with FC1242 cells, randomized in four groups receiving, respectively, vehicle (CTRL, n=10), AT38 only (AT38, n=10), mTERT-specific mouse CTLs only (TERT-ACT, n=10), AT38+mTERT-specific mouse CTLs (n=10). Tumor growth was evaluated by in vivo imaging: a representative image for each analyzed time point was reported (left panel). Therapeutic efficacy was evaluated over time in terms of tumor progression (middle panels) and survival (right panel). Data are reported as mean±SD of a representative experiment of two independent replicates. Statistical analysis was performed using one-way ANOVA followed by Tukey’s test for tumor growth and Mantel-Haenszel (long-rank) test for survival. (B) KPC mice were enrolled in four groups receiving, respectively, vehicle (CTRL), AT38 only (AT38), mTERT-specific mouse CTLs only (TERT-ACT), AT38+mTERT-specific mouse CTLs (AT38+TERT ACT). Tumor growth was evaluated by high-resolution ultrasound images of pancreatic tumor in KPC mice before (-, left panel) and 10 days after treatment (+, left panel) and shown as waterfall plots (right panel) of therapeutic response. (C) Kaplan-Meier curves for overall survival of KPC mice with invasive disease untreated (n=25) or treated with AT38 (n=20), TERT-ACT (n=15) or combined approach (n=20). Statistical analysis was performed using Mantel-Haenszel (long-rank) test. ACT, adoptive cell therapy; ANOVA, analysis of variance; CTL, cytotoxic T lymphocyte; PDAC, pancreatic ductal adenocarcinoma; TERT, telomerase.

Article Snippet: KPC mice were kindly supplied by Dr D Tuveson (Cold Spring Harbor Laboratory, New York, USA).

Techniques: In Vivo Imaging, Drug discovery, Clinical Proteomics

Nanoparticle-based therapeutic strategies for enhanced PDAC immunotherapy.

Journal: Pharmaceutics

Article Title: Nanoparticle-Based Therapeutic Strategies for Enhanced Pancreatic Ductal Adenocarcinoma Immunotherapy

doi: 10.3390/pharmaceutics14102033

Figure Lengend Snippet: Nanoparticle-based therapeutic strategies for enhanced PDAC immunotherapy.

Article Snippet: gemcitabine-loaded poly (lactic-co-glycolic acid) (PLGA) nanoparticles + M2-like macrophages peptides (M2pep) +PD-L1 antibody , biomimetic dual-targeting nanomedicine , iv , elimination of PD-L1-positive macrophages and the downregulation of PD-L1 expression; reprogrammed macrophages, downregulated PD-L1 expression, and sustained T cell populations, , 2022 , [ ] .

Techniques: Modification, Molecular Weight, Clinical Proteomics, Injection, Polymer, Expressing, Recombinant, Liposomes, Irradiation, In Situ